Cardiac Biomarker

Cardiac Biomarker Market Outlook

The global cardiac biomarker market is projected to reach approximately USD 7.5 billion by 2035, growing at a CAGR of around 8.2% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, advancements in biomarker technology, and the rising demand for early diagnosis and effective patient management. As cardiovascular diseases continue to be a leading cause of mortality worldwide, the focus on innovative diagnostic solutions has intensified. Furthermore, the surge in point-of-care testing and home care services has opened new avenues for market expansion. The integration of artificial intelligence and machine learning in cardiac biomarkers is also expected to revolutionize the sector by enhancing diagnostic accuracy and efficiency, which in turn fosters market growth.

Growth Factor of the Market

The cardiac biomarker market is witnessing a robust growth driven by several critical factors. Firstly, the rise in the elderly population is linked to a higher incidence of heart-related diseases, thus escalating the demand for cardiac biomarkers. Additionally, ongoing research and development activities aimed at discovering novel biomarkers are further propelling market expansion. The growth of healthcare infrastructure and increasing healthcare expenditures globally are also contributing to the market's positive outlook. Moreover, an increase in awareness and education regarding heart health significantly impacts demand for early diagnostic tools, making cardiac biomarkers essential in clinical practices. The push for personalized medicine, which necessitates precise and tailored diagnostic approaches, continues to reinforce the prominence of cardiac biomarkers in modern healthcare.

Key Highlights of the Market

• The global cardiac biomarker market is expected to witness significant growth, driven by technological advancements.
• Increased prevalence of cardiovascular diseases globally, leading to higher demand for early diagnosis.
• Growing interest in point-of-care testing to facilitate immediate results and patient care.
• Extensive research and innovation focused on discovering new biomarkers for better diagnostic accuracy.
• Rising healthcare expenditures and improved access to diagnostic services amplifying market potential.

By Product Type

Troponin:

Troponin is a key cardiac biomarker, specifically utilized for diagnosing myocardial infarction. It is a protein complex involved in muscle contraction and is released into the bloodstream when heart muscle is damaged. The increasing awareness of the importance of rapid diagnosis in acute coronary syndromes has bolstered the troponin market segment. The availability of high-sensitivity troponin tests has further enhanced diagnostic efficacy, making it a preferred choice among healthcare professionals. Consequently, the demand for troponin testing is on the rise, as clinicians seek to provide timely interventions for patients presenting with chest pain or other cardiac-related symptoms. This product type is expected to maintain a leading position in the cardiac biomarker market due to its clinical reliability and relevance.

CK-MB:

Creatine Kinase-MB (CK-MB) is another important cardiac biomarker used primarily to diagnose myocardial infarction. Compared to troponin tests, CK-MB can provide a quicker indication of myocardial injury. The segment's growth can be attributed to the increased use of CK-MB in emergency settings, particularly in hospitals where rapid decision-making is critical. CK-MB is particularly advantageous for detecting reinfarction since its levels rise and fall more quickly than troponin. However, while CK-MB remains relevant, its market share may decline slightly as more healthcare facilities adopt high-sensitivity troponin tests as the gold standard for myocardial infarction diagnosis.

BNP:

Brain Natriuretic Peptide (BNP) is crucial in diagnosing and managing heart failure. Elevated levels of BNP in the bloodstream are indicative of increased cardiac pressure and volume overload. The growing prevalence of heart failure, driven by aging populations and lifestyle-related factors, has led to an increased focus on BNP testing. The ability of BNP to provide early insights into heart failure exacerbation makes it an essential tool in emergency departments and outpatient settings. Additionally, as healthcare providers shift towards more integrated heart failure management strategies, the demand for BNP testing is anticipated to expand further, marking it as a significant player in the cardiac biomarker market.

Myoglobin:

Myoglobin serves as a useful biomarker for the early detection of myocardial infarction due to its rapid release into the bloodstream following muscle injury. It is particularly beneficial in emergency medicine for its ability to provide timely information following chest pain presentation. However, while myoglobin testing is valuable, its clinical use is somewhat limited due to a lack of specificity for cardiac damage. Nevertheless, the segment is expected to maintain a stable share in the market, especially in conjunction with other biomarkers, as clinicians aim to utilize a comprehensive approach to cardiac assessment.

Others:

This category encompasses various biomarkers that can assist in diagnosing cardiac conditions, including newer markers such as high-sensitivity C-reactive protein and various peptides. As research continues to explore additional biomarkers for their clinical utility, this segment is likely to see growth driven by innovations and increasing awareness of their significance. Emerging studies on the role of inflammation in cardiovascular disease highlight the potential for these alternative biomarkers to provide valuable insights for patient management. As a result, the 'Others' segment is anticipated to gain traction, reflecting the ongoing evolution in cardiac biomarker research.

By Application

Myocardial Infarction:

Myocardial infarction (MI) represents a leading application area for cardiac biomarkers, as early and accurate diagnosis is crucial for effective treatment. Biomarkers such as troponin and CK-MB are predominantly used to confirm the diagnosis of MI, allowing for timely intervention. The rising incidence of heart attacks globally, coupled with an increased focus on rapid assessment in emergency settings, is significantly driving the demand for MI-related cardiac biomarkers. As healthcare providers seek to improve patient outcomes through prompt diagnosis and management, this application segment is expected to witness sustained growth, underpinned by advances in biomarker testing technologies.

Heart Failure:

Heart failure is another critical application area for cardiac biomarkers, with BNP and NT-proBNP being the most commonly used markers. These biomarkers are instrumental in diagnosing heart failure and monitoring treatment efficacy. The escalating prevalence of heart failure—attributable to factors such as aging populations and rising rates of hypertension and diabetes—has led to an increased focus on improving early detection methods. The ability of BNP testing to provide actionable insights for timely interventions positions it as a cornerstone in heart failure management, fostering growth in this application segment.

Cardiac Surgery:

Cardiac surgery applications for biomarkers are gaining traction as surgeons and clinicians increasingly rely on biomarkers to predict outcomes and assess post-operative complications. Biomarkers can provide insights into myocardial injury and guide postoperative care strategies. The rising number of cardiac procedures globally, coupled with advancements in surgical techniques, has amplified the need for effective biomarker monitoring in surgical settings. As hospitals and surgical centers prioritize patient safety and recovery, the cardiac surgery application segment is poised for growth, driven by a commitment to enhanced patient care.

Others:

This category encompasses various other applications of cardiac biomarkers, including risk stratification and prognosis in cardiovascular disease management. These biomarkers can assist in predicting adverse cardiac events, enabling healthcare providers to tailor intervention strategies effectively. As research continues to expand the understanding of the role of biomarkers in cardiovascular health, the 'Others' segment is expected to see growth. The ability to integrate biomarker testing into routine cardiovascular assessments enhances the overall management of patients, reinforcing the importance of this category in the broader cardiac biomarker market.

By Distribution Channel

Hospitals:

The hospital distribution channel remains a dominant segment for cardiac biomarker testing, driven by the high volume of patients requiring cardiac assessments. Hospitals are often equipped with advanced laboratory facilities that facilitate accurate and timely testing. With the growing emphasis on rapid diagnostics in emergency departments, hospitals are increasingly utilizing cardiac biomarkers to enhance patient care. The integration of point-of-care testing equipment within hospital settings further supports this channel’s growth, allowing for immediate results and expedited decision-making. As hospitals continue to expand their diagnostic capabilities, this distribution channel is expected to maintain its significant market share.

Diagnostic Laboratories:

Diagnostic laboratories play a vital role in the cardiac biomarker market by providing specialized testing services. These laboratories are equipped with advanced technology and skilled professionals to deliver accurate diagnostic results. The increasing outsourcing of laboratory services by hospitals and healthcare providers contributes to the growth of this distribution channel. Moreover, as the demand for comprehensive cardiac assessments rises, diagnostic labs are expanding their testing portfolios to include a wider range of biomarkers. This trend positions the diagnostic laboratory segment for continued growth, reflecting the critical role these facilities play in patient management.

Point-of-Care Testing:

Point-of-care testing (POCT) is rapidly transforming the cardiac biomarker landscape, allowing for immediate testing and results at the site of patient care. POCT devices are particularly advantageous in emergency and outpatient settings, where time-sensitive decisions are paramount. The increasing adoption of POCT in managing cardiovascular diseases is driven by the need for rapid diagnostics and improved patient outcomes. As technology advances, the accuracy and reliability of POCT devices continue to enhance, paving the way for more widespread implementation in clinical practice. This distribution channel is projected to grow significantly as healthcare systems prioritize convenience and efficiency in patient care.

Others:

This category includes various alternative distribution channels, such as online platforms and direct sales to healthcare providers. The rise of telemedicine and digital health solutions has prompted an increase in the availability of cardiac biomarkers through innovative channels. As consumers and healthcare providers seek more convenient access to diagnostic testing, this segment is expected to expand. The shift towards decentralized healthcare, supported by increased investment in digital health technologies, will likely enhance the reach and accessibility of cardiac biomarkers, ultimately driving growth in the 'Others' distribution channel.

By Biomarker Type

Natriuretic Peptides:

Natriuretic peptides, particularly BNP and NT-proBNP, are critical biomarkers in diagnosing and managing heart failure. Elevated levels of these peptides indicate cardiac stress and help healthcare providers assess the severity of heart failure. The increasing prevalence of heart failure worldwide, fueled by aging populations and lifestyle-related risk factors, has led to heightened interest and use of natriuretic peptides in clinical practice. As healthcare professionals increasingly rely on these biomarkers for timely interventions, the natriuretic peptides segment is projected for significant growth in the cardiac biomarker market.

Creatine Kinase:

Creatine kinase (CK) is a significant biomarker used to assess muscle damage and is especially relevant in the context of myocardial infarction. The CK-MB fraction, in particular, is utilized to diagnose cardiac events. The growth of this biomarker type can be attributed to its ability to provide quick insights into myocardial injury. However, as high-sensitivity troponin tests become the standard for MI diagnosis, the reliance on CK may start to wane in some clinical settings. Nevertheless, the segment will maintain its relevance due to its established clinical utility and historical significance in cardiac assessment.

Troponins:

Troponins are regarded as the gold standard biomarker for diagnosing and managing myocardial infarction. Their high specificity and sensitivity make them invaluable in emergency departments for rapid diagnosis. The troponin segment is poised for substantial growth as healthcare providers continue to adopt high-sensitivity assays that enable earlier detection of cardiac injury. Furthermore, ongoing research into the role of troponins in risk assessment and prognosis will likely expand their clinical applications beyond acute myocardial injury. As such, troponins will remain a dominant player in the cardiac biomarker market.

Myoglobin:

Myoglobin is a biomarker that can provide early information regarding myocardial injury, particularly in acute settings. As a protein released from damaged muscle fibers, myoglobin levels increase rapidly following an ischemic event. While myoglobin is less specific for cardiac injury compared to troponin, its quick release makes it a useful tool in conjunction with other markers. The myoglobin segment is expected to maintain a stable presence in the market, albeit its use may be overshadowed by more specific biomarkers in the future.

Others:

In addition to the primary biomarkers mentioned, this category includes various emerging markers under investigation for their potential in cardiology. These biomarkers may include inflammatory markers, novel peptides, and other molecules that could enhance the ability to assess cardiovascular risk. As research evolves and the understanding of cardiovascular pathology deepens, several of these emerging biomarkers may find clinical utility, thus expanding the breadth of cardiac biomarker applications. The ongoing investigation into these alternative biomarkers is expected to bolster market growth in this segment.

By Region

The North American cardiac biomarker market is anticipated to dominate, accounting for approximately 40% of the global market share by 2035. This dominance is attributed to the advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and increased investment in healthcare innovation within the region. The presence of major players in the medical diagnostics industry, coupled with the rising trend in point-of-care testing, further strengthens North America's position. The region is projected to grow at a CAGR of around 7.5% over the forecast period, reflecting ongoing efforts to enhance cardiac care through advanced biomarker technologies.

In Europe, the cardiac biomarker market is also expected to see substantial growth, driven by the growing elderly population and rising rates of heart-related ailments. The European market is projected to capture around 30% of the global market share by 2035. The emphasis on preventive healthcare and early diagnosis within European healthcare systems supports strong demand for cardiac biomarkers. Additionally, government initiatives aimed at improving cardiovascular care and increasing investment in medical research are expected to bolster market development in this region. Together, these factors will contribute to a robust growth trajectory in the European cardiac biomarker market.

Opportunities

The cardiac biomarker market is ripe with opportunities, particularly given the increasing focus on personalized medicine and the importance of early diagnosis in improving patient outcomes. As healthcare systems shift towards more patient-centered approaches, the integration of advanced diagnostic technologies will be crucial for the development of innovative cardiac biomarker solutions. Moreover, the growing trend of telemedicine and remote monitoring can facilitate broader access to testing, allowing patients to receive timely diagnoses from the comfort of their homes. This trend presents new avenues for market players to explore, particularly in developing point-of-care testing solutions that are efficient, reliable, and user-friendly. Additionally, partnerships between biomarker manufacturers and healthcare providers can enhance clinical trial research, leading to the discovery of novel biomarkers and expanding their applications.

Another promising opportunity lies in the global expansion of healthcare services, particularly in emerging markets. Increasing investment in healthcare infrastructure, coupled with a rising awareness of cardiovascular health, creates a fertile environment for the adoption of cardiac biomarkers. This scenario showcases a significant opportunity for companies to position themselves strategically and cater to the burgeoning demand in these regions. Additionally, the continuous introduction of new technologies and innovations, such as digital health solutions and artificial intelligence for data analysis, can enhance the capabilities of cardiac biomarker testing. As the market evolves, embracing these technological advancements will be instrumental for companies looking to capture a larger market share and improve patient care outcomes.

Threats

Despite the promising outlook for the cardiac biomarker market, several threats could impede growth. One major concern is the stringent regulatory environment governing the approval and commercialization of new diagnostic tests. Delays in regulatory approvals can hinder the timely introduction of innovative biomarker tests, potentially affecting market dynamics. Moreover, the high costs associated with research and development, coupled with the complexity of clinical validation for new biomarkers, may deter some companies from investing in this space. As competition intensifies, companies may also face pressure to reduce prices, affecting profit margins and limiting reinvestment into further innovation.

Another potential threat arises from the rapid technological advancements within the healthcare sector. The emergence of alternative diagnostic methods, such as non-invasive imaging and artificial intelligence-driven assessments, may overshadow traditional cardiac biomarker testing. As healthcare providers increasingly seek efficiency and cost-effectiveness, there is a risk that conventional biomarkers may be perceived as outdated. Additionally, the growing trend of patient self-monitoring and the use of wearable devices may shift the focus away from clinical testing environments, posing a challenge to established cardiac biomarker testing practices. Companies must navigate these evolving dynamics to maintain relevance in a shifting landscape.

Competitor Outlook

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Ortho Clinical Diagnostics
• Beckman Coulter
• bioMérieux
• Philips Healthcare
• Quidel Corporation
• PerkinElmer
• Cardiac Biomarkers, Inc.
• Medtronic
• GE Healthcare
• Sysmex Corporation
• F. Hoffmann-La Roche AG

The competitive landscape of the cardiac biomarker market is characterized by the presence of several key players that are actively engaged in research, development, and commercialization of innovative diagnostic solutions. Major corporations, such as Abbott Laboratories and Roche Diagnostics, dominate the market due to their extensive product portfolios and strong brand recognition. These companies are continuously investing in R&D to develop new biomarkers and improve existing diagnostic methodologies. Strategic partnerships and collaborations with hospitals and healthcare institutions are also common as companies seek to enhance their market presence and deliver value-based care to patients. Furthermore, the competitive environment is shaped by the increasing trend of mergers and acquisitions, allowing larger entities to expand their capabilities and consolidate market share.

Abbott Laboratories is a notable leader in the cardiac biomarker sector, particularly with its advanced troponin testing solutions. The company is known for its commitment to innovation and has developed high-sensitivity assays that enhance diagnostic accuracy in detecting myocardial infarction. Additionally, Abbott’s ongoing focus on integrating digital health solutions into its product offerings showcases its commitment to advancing patient care. Similarly, Roche Diagnostics has established itself as a formidable competitor through its extensive range of cardiac biomarkers and diagnostic testing platforms. The company’s strong emphasis on research and collaboration with healthcare professionals enables it to stay at the forefront of the market, continuously enhancing its portfolio to meet the evolving needs of clinicians and patients alike.

Siemens Healthineers is another significant player, leveraging its expertise in diagnostics and imaging technologies to deliver comprehensive cardiac testing solutions. The company aims to provide integrated diagnostics that facilitate timely decision-making in clinical settings. Siemens’ investments in artificial intelligence and digital health innovations further enhance its capabilities, positioning it as a forward-thinking competitor in the cardiac biomarker market. Additionally, Medtronic’s commitment to cardiac health through its innovative technologies and devices aligns well with the growing demand for integrated care solutions. Medtronic’s focus on delivering value-based healthcare solutions strengthens its market presence and allows it to respond effectively to the challenges faced in managing cardiovascular diseases.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 PerkinElmer
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 GE Healthcare
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Beckman Coulter
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 bioMérieux
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Philips Healthcare
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Quidel Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Sysmex Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Abbott Laboratories
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Siemens Healthineers
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 F. Hoffmann-La Roche AG
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Cardiac Biomarkers, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Ortho Clinical Diagnostics
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cardiac Biomarker Market, By Application
    • 6.1.1 Myocardial Infarction
    • 6.1.2 Heart Failure
    • 6.1.3 Cardiac Surgery
    • 6.1.4 Others
  • 6.2 Cardiac Biomarker Market, By Product Type
    • 6.2.1 Troponin
    • 6.2.2 CK-MB
    • 6.2.3 BNP
    • 6.2.4 Myoglobin
    • 6.2.5 Others
  • 6.3 Cardiac Biomarker Market, By Biomarker Type
    • 6.3.1 Natriuretic Peptides
    • 6.3.2 Creatine Kinase
    • 6.3.3 Troponins
    • 6.3.4 Myoglobin
    • 6.3.5 Others
  • 6.4 Cardiac Biomarker Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Laboratories
    • 6.4.3 Point-of-Care Testing
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Cardiac Biomarker Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cardiac Biomarker market is categorized based on

By Product Type

• Troponin
• CK-MB
• BNP
• Myoglobin
• Others

By Application

• Myocardial Infarction
• Heart Failure
• Cardiac Surgery
• Others

By Distribution Channel

• Hospitals
• Diagnostic Laboratories
• Point-of-Care Testing
• Others

By Biomarker Type

• Natriuretic Peptides
• Creatine Kinase
• Troponins
• Myoglobin
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Ortho Clinical Diagnostics
• Beckman Coulter
• bioMérieux
• Philips Healthcare
• Quidel Corporation
• PerkinElmer
• Cardiac Biomarkers, Inc.
• Medtronic
• GE Healthcare
• Sysmex Corporation
• F. Hoffmann-La Roche AG